| Old Articles: <Older 6821-6830 Newer> |
|---|
 |
Pharmaceutical Executive
October 1, 2010 |
Decisive Strategy Wins the Market A clear, consistent approach to the competition can deliver big gains in market share; six decisions lead the way.   |
Pharmaceutical Executive
October 1, 2010 |
Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives. |
Pharmaceutical Executive
October 1, 2010
William Looney |
Community: The Business of Life There is a practical lesson of reaching forward to tap the human community - and the moral connection - that will preserve the "license to operate" in the biopharmaceuticals business: the business of life. |
The Motley Fool
October 25, 2010
Travis Hoium |
Savient Pharmaceuticals Shares Plunged: What You Need to Know Savient Pharmaceuticals shares took a nosedive down 43% on Monday as the company failed to find a buyer for the firm. |
The Motley Fool
October 25, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Standpoint Capital believes that ExxonMobil, Quest Diagnostics, and Lockheed Martin have nowhere to go but up. |
The Motley Fool
October 24, 2010
Jeremy Phillips |
Time to Sell Medifast? Is it time to sell Medifast? Let's look at price, valuation, margins, and liquidity to see. |
CRM
October 2010
Lauren McKay |
Market Focus: Healthcare--A Healthy Dose of Social Media One provider shows how to join consumers in social networks without compromising a secure relationship. |
The Motley Fool
October 22, 2010
Anand Chokkavelu |
7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential. |
The Motley Fool
October 22, 2010
Brian Orelli |
No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further. |
The Motley Fool
October 22, 2010
Roger Friedman |
3 Health-Care Stocks for Your Watchlist There's money to be made in health care. But finding the right plays, especially among health care providers, can prove confounding. |
| <Older 6821-6830 Newer> Return to current articles. |
